Parkview Health

Parkview Health Research Repository
Pharmacy

Parkview Research Center

12-2022

Evaluation of Intravenous Loop Diuretic Use in Acute
Decompensated Heart Failure in a Community Hospital
Catherine Eichler PharmD
Cole Luty PharmD
Kris Howard PharmD, AACC

Follow this and additional works at: https://researchrepository.parkviewhealth.org/pharma
Part of the Pharmacy and Pharmaceutical Sciences Commons

Evaluation of Intravenous Loop Diuretic Use in Acute
Decompensated Heart Failure in a Community Hospital
Catherine Eichler, PharmD; Cole Luty, PharmD, BCPS; Kris Howard, PharmD, AACC
Parkview Regional Medical Center
Fort Wayne, Indiana

OBJECTIVE
•

RESULTS

To characterize the use of intravenous loop diuretics in patients hospitalized
with fluid overload secondary to acute decompensated heart failure (ADHF)
within the heart failure service of a community hospital.

Figure 1: Top 10 Most Utilized Initial Regimens (n=524)

BACKGROUND
• Loop diuretics cause water excretion renally by inhibiting the sodium-potassiumchloride cotransporter in the ascending loop of Henle to reduce sodium and
chloride reabsorption.1
• The loop diuretic drug class includes furosemide, bumetanide, torsemide and
ethacrynic acid.1 Furosemide is the most utilized loop diuretic in heart failure.2
• Furosemide, bumetanide, and torsemide are on formulary for this facility.
• Prompt treatment with loop diuretics is recommended for fluid overload in ADHF
by the 2022 AHA/ACC/HFSA Heart Failure Management Guidelines.2
• High doses of loop diuretics have been associated with adverse effects such as
acute kidney injury (AKI) and hypokalemia.1
• There is lack of data on the optimal regimen for empiric diuresis in ADHF.3,4

RESULTS
Table 2: Therapy Characteristics
IV loop diuretic duration (days), mean ± SD
Total loop diuretic duration (days), mean ± SD
Frequency of transition to PO loop diuretic, n (%)
Additional IV non-loop diuretic administered, n (%)

3.62 ± 2.72
4.98 ± 3.75
422 (72)
18 (3)

Table 3: Incidence of Side Effects
Acute kidney injury, n (%)
Hypokalemia, n (%)

86 (14)
237 (40)

Figure 5: Occurrence of AKI in CKD Stage 1-4 vs no CKD (n=86)
Figure 2: Frequency Classifications Throughout Therapy Changes (n=599)

METHODS
DISCUSSION & CONCLUSIONS

• This is an Institutional Review Board (IRB) approved retrospective study from
September 1, 2020 to December 31, 2021.
*defined as q6h, q8h, q12h, q24h

Inclusion Criteria

Exclusion Criteria

• ≥ 18 years old
• ADHF diagnosis
• Continuous infusion or more than
1 bolus dose of loop diuretic
Primary Endpoints:
• Frequency of the initial
loop diuretic
• Description of subsequent
regimen adjustments

• Chronic kidney disease (CKD)
stage 5 receiving dialysis
• Cirrhosis
• Thoracentesis during admission

Secondary Endpoints:
• Urine output
• IV loop diuretic duration
• Total loop diuretic duration
• Additional IV non-loop diuretics administered
• AKI: a SCr increase from baseline of 0.3 mg/dL
within 48 hours or 1.5x within 7 days
• Hypokalemia: potassium level < 3.5 mEq/L

RESULTS
Table 1: Patient Demographics

Total patient, n
Average age, years ± SD
Female sex, n (%)
Ejection fraction, mean ± SD
Home loop diuretic prior to admission, n (%)
CrCl at admission, mean ± SD
Past medical history CKD Stage 1-4, n (%)

Figure 3: First Adjusted Regimens Following Initial Once Doses (n=279)

599
71.5 ±13.4
223 (37)
40.1 ± 16.2
322 (54)
58.7 ± 35.2
371 (62)

Figure 4: Average Urine Output Based on Estimated 24 Hour dose (n=406)

• There were 36 initial regimens, underscoring the need for standardization. Top
10 most utilized regimens account for 87% of total encounters.
• Majority of regimens following once doses were intravenous and included
furosemide, following trends in practice and guideline recommendations. 2
• Highest average urine output was associated with bumetanide IV 9mg;
however, it wasn’t highly utilized. 24 hour doses of furosemide IV 80mg,
120mg, and 160mg account for ~50% of regimens with similar urine outputs.
Initial regimens could be streamlined to equal those 24 hour furosemide doses.
• Minimal usage of additional non-loop IV diuretics implies the loop diuretic
regimens utilized provided adequate congestion management.
• Incidence of hypokalemia warrants further investigation of potassium
supplementation for specific loop diuretic regimens.
• Higher incidence of AKI in CKD indicates additional monitoring and conservative
loop diuretic dosing may be appropriate.
• This study was limited by inconsistent urine output documentation and patientspecific nature of loop diuretic dosing in ADHF.
• To conclude the best loop diuretic regimen(s), further evaluation of in-patient
dosing compared to home diuretic dosing and additional diuresis efficacy
endpoints such as clinical signs of congestion and/or weight changes is needed.
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